Download MendeleyDiscovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2 alpha.
Mailyan, A.K., Mata, G., Beatty, J.W., Drew, S.L., Fournier, J., Yu, K., Gal, B., Kalisiak, J., Yan, X., Tran, A., Su, Y., Rosen, B.R., Jeffrey, J.L., Hardman, C., Epplin, M., Ginn, E., Sun, M., Chen, A., Fabila, P., Sivick, K.E., Schweickert, P.G., Piovesan, D., Meleza, C., Pham, A.T., Chen, P.Y., Jin, L., Walters, M.J., Walker, N.P., Kwon, H.J., Leleti, M.R., Powers, J.P., Lawson, K.V.(2026) J Med Chem
- PubMed: 42246926 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.5c03724
- Primary Citation Related Structures:
9I64 - PubMed Abstract:
Hypoxia-inducible factor 2α (HIF-2α) is recognized as a key oncogenic driver in clear cell renal cell carcinoma (ccRCC), the most prevalent type of kidney cancer. Here, we describe the discovery of a highly potent and selective tetralin-based HIF-2α inhibitor, casdatifan ( 61 ), originating from previously identified tetrahydroquinolines reported in the Part 1 companion manuscript. Casdatifan demonstrates a potentially best-in-class clinical profile. In a healthy volunteer study (NCT05117554), casdatifan exhibited a favorable pharmacokinetic profile, with an approximate 24-h half-life suitable for once-daily oral administration. Casdatifan has shown promising clinical activity in the ARC-20 ccRCC platform study, both as monotherapy and in combination with the VEGFR tyrosine kinase inhibitor (TKI) cabozantinib. Currently, casdatifan is being evaluated in a Phase 3 trial in combination with cabozantinib (NCT07011719) in patients with advanced ccRCC.
- Arcus Biosciences, Inc., Hayward, California 94545, United States.
Organizational Affiliation:
